Pharming announces a recommended cash offer to the shareholders of Abliva

Pharming Group N.V., through the wholly-owned subsidiary Pharming Technologies B.V., announces a recommended cash offer to the shareholders of Abliva AB to tender all shares in Abliva to Pharming at a price of SEK 0.45 in cash per share. The offer values all outstanding shares in Abliva at approximately SEK 725 million.

Pharming is a global biopharmaceutical company commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. Pharming’s shares are admitted to trading on Euronext Amsterdam and its American Depositary Shares (ADSs) are admitted to trading on Nasdaq Global Market.

Abliva discovers and develops medicines for the treatment of mitochondrial disease. Abliva is based in Lund, and its shares are admitted to trading on Nasdaq Stockholm, Small Cap.

Pharming is advised by Mannheimer Swartling on the offer.

Cookies

This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.